Case Study: Fortune 500 Global BioPharma Company reduces EU price erosion from 2.5% to 1.5% with Model N Revvy Global Price Management

Fortune 500 Global BioPharma Company - Customer Case Study

A Top‑5 global biopharma company with 30 years of experience and products reaching over 25 million patients faced escalating price erosion across 60+ countries. Its legacy pricing system and manual processes could not meet complex regulatory requirements or coordinate global launches, leaving the manufacturer with weak negotiating positions and rising compliance risk.

The company implemented Revvy Global Price Management by Model N — a cloud-based global pricing database with governance workflows, predictive analytics and automated price change management. The solution automated thousands of price updates, reduced regulatory non‑compliance, cut European price erosion from 2.5% to 1.5% (a 40% reduction), and delivered up to $30M in annual savings through analytics-driven pricing decisions.